Weekly highlight of top insider buys: Pfizer Inc. (PFE, Financial), Morgan Stanley (MS, Financial), Celgene Corp. (CELG, Financial), and Chesapeake Energy Corp. (CHK, Financial).
Business Unit President of Pfizer Inc., David S. Simmons, bought 2,000 shares on 8/03/2011 at an average price of $17.36. Pfizer Inc. is a research-based, global pharmaceutical company that discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. Pfizer Inc. has a market cap of $137.16 billion; its shares were traded at around $17.36 with a P/E ratio of 7.8 and P/S ratio of 2. The dividend yield of Pfizer Inc. stocks is 4.6%. Pfizer Inc. had an annual average earnings growth of 1.2% over the past 10 years.
On August 2, Pfizer Inc. reported financial results for second-quarter 2011. Second-quarter 2011 revenues were $17.0 billion, a decrease of 1% compared with the year-ago quarter. Second-quarter 2011 revenues were reduced by $1.5 billion, or 9%, due to the impact of the loss of exclusivity for several products in certain geographies, and $158 million, or 1%, due to U.S. healthcare reform.
Pfizer Inc. is in the portfolios of Joel Greenblatt, John Keeley, Jean-Marie Eveillard, Michael Price, Lee Ainslie, David Einhorn, Kenneth Fisher, James Barrow, Richard Snow, Donald Yacktman, NWQ Managers, Irving Kahn, David Williams, Brian Rogers, John Hussman, Prem Watsa, Robert Bruce, PRIMECAP Management, Dodge & Cox, Ruane Cunniff, David Dreman, David Tepper, Charles Brandes, Mark Hillman, Edward Owens, Chris Davis, George Soros, Hotchkis & Wiley, Ronald Muhlenkamp, and Mario Gabelli.
Last week, Business Unit President David S. Simmons bought 2,000 shares of PFE stock. Executive Vice President Douglas M. Lankler sold 7,541 shares in May.
Co-President Institutional Securities Paul J. Taubman, bought 50,000 shares on 08/04/2011 at an average price of $19.7. Morgan Stanley is a preeminent global financial services firm that maintains market positions in each of its three primary businesses: securities, asset management and credit services. Morgan Stanley has a market cap of $30.43 billion; its shares were traded at around $19.7 with a P/E ratio of 35.2 and P/S ratio of 1. The dividend yield of Morgan Stanley stocks is 1%. Morgan Stanley had an annual average earnings growth of 2.1% over the past 10 years.
Morgan Stanley is in the portfolios of Ken Heebner, Brian Rogers, Richard Pzena, Bruce Berkowitz, Robert Olstein, Mario Gabelli, and George Soros.
On July 21, Morgan Stanley reported net revenues of $9.3 billion for the second quarter ended June 30, 2011 compared with $8.0 billion a year ago. For the current quarter, income from continuing operations applicable to Morgan Stanley was $1.2 billion compared with $1.4 billion in the prior year quarter.
This month, President and CEO James P. Gorman, CFO Ruth Porat, Director Hutham S. Olayan, Co-President Institutional Securities Paul J. Taubman, and Director James W. Owens bought shares of MS stock. COO James A. Rosenthal sold 8,000 shares in July.
Director of Celgene Corp., Ernest Mario, bought 105,000 shares during the past week at an average price of $55.51. Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $25.69 billion; its shares were traded at around $55.51 with a P/E ratio of 20 and P/S ratio of 7.
On July 28, Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69. Celgene posted non-GAAP net income of $811 million, or non-GAAP diluted earnings per share of $1.72, for the first six months of 2011 as compared to non-GAAP net income of $618 million or non-GAAP diluted earnings per share of $1.32 in 2010.
Celgene Corp. is in the portfolios of John Hussman, Kenneth Fisher, and Mario Gabelli.
This month, CFO Jacqualyn A. Fouse, Director Ernest Mario, and Director Rodman L. Drake bought shares of CELG stock. Director Gilla Kaplan sold 20,000 shares in June.
Director of Chesapeake Energy Corp., V. Burns Hargis, bought 1,500 shares on 08/04/2011 at an average price of $31.35. Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake Energy Corp. has a market cap of $20.62 billion; its shares were traded at around $31.35 with a P/E ratio of 10.7 and P/S ratio of 2.2. The dividend yield of Chesapeake Energy Corp. stocks is 1.1%. Chesapeake Energy Corp. had an annual average earnings growth of 9.8% over the past 10 years.
Chesapeake Energy Corp. is in the portfolios of Richard Snow, T Boone Pickens, Ruane Cunniff, Ronald Muhlenkamp, David Dreman, Charles Brandes, Arnold Schneider, Carl Icahn, and Mario Gabelli.
On July 28, Chesapeake Energy Corporation announced its 2011 second quarter financial and operational results. For the quarter, Chesapeake reported net income to common stockholders of $467 million ($0.68 per fully diluted common share), operating cash flow of $1.207 billion (defined as cash flow from operating activities before changes in assets and liabilities) and EBITDA of $1.289 billion.
In June, Chairman & CEO Aubrey K. Mcclendon and Executive Vice President & CFO Domenic J. Dell'osso Jr. bought shares of CHK stock. Director V. Burns Hargis bought 1,500 shares this month. Senior Vice President Human & Corporate Resources Martha A. Burger sold 40,000 shares this month.
For the complete list of stocks that bought by their company executives, go to: Insider Buys.
Pfizer Inc. (PFE): Business Unit President David S. Simmons Bought 2,000 Shares
Business Unit President of Pfizer Inc., David S. Simmons, bought 2,000 shares on 8/03/2011 at an average price of $17.36. Pfizer Inc. is a research-based, global pharmaceutical company that discovers and develops innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. Pfizer Inc. has a market cap of $137.16 billion; its shares were traded at around $17.36 with a P/E ratio of 7.8 and P/S ratio of 2. The dividend yield of Pfizer Inc. stocks is 4.6%. Pfizer Inc. had an annual average earnings growth of 1.2% over the past 10 years.
On August 2, Pfizer Inc. reported financial results for second-quarter 2011. Second-quarter 2011 revenues were $17.0 billion, a decrease of 1% compared with the year-ago quarter. Second-quarter 2011 revenues were reduced by $1.5 billion, or 9%, due to the impact of the loss of exclusivity for several products in certain geographies, and $158 million, or 1%, due to U.S. healthcare reform.
Pfizer Inc. is in the portfolios of Joel Greenblatt, John Keeley, Jean-Marie Eveillard, Michael Price, Lee Ainslie, David Einhorn, Kenneth Fisher, James Barrow, Richard Snow, Donald Yacktman, NWQ Managers, Irving Kahn, David Williams, Brian Rogers, John Hussman, Prem Watsa, Robert Bruce, PRIMECAP Management, Dodge & Cox, Ruane Cunniff, David Dreman, David Tepper, Charles Brandes, Mark Hillman, Edward Owens, Chris Davis, George Soros, Hotchkis & Wiley, Ronald Muhlenkamp, and Mario Gabelli.
Last week, Business Unit President David S. Simmons bought 2,000 shares of PFE stock. Executive Vice President Douglas M. Lankler sold 7,541 shares in May.
Morgan Stanley (MS): Co-President Institutional Securities Paul J. Taubman Bought 50,000 Shares
Co-President Institutional Securities Paul J. Taubman, bought 50,000 shares on 08/04/2011 at an average price of $19.7. Morgan Stanley is a preeminent global financial services firm that maintains market positions in each of its three primary businesses: securities, asset management and credit services. Morgan Stanley has a market cap of $30.43 billion; its shares were traded at around $19.7 with a P/E ratio of 35.2 and P/S ratio of 1. The dividend yield of Morgan Stanley stocks is 1%. Morgan Stanley had an annual average earnings growth of 2.1% over the past 10 years.
Morgan Stanley is in the portfolios of Ken Heebner, Brian Rogers, Richard Pzena, Bruce Berkowitz, Robert Olstein, Mario Gabelli, and George Soros.
On July 21, Morgan Stanley reported net revenues of $9.3 billion for the second quarter ended June 30, 2011 compared with $8.0 billion a year ago. For the current quarter, income from continuing operations applicable to Morgan Stanley was $1.2 billion compared with $1.4 billion in the prior year quarter.
This month, President and CEO James P. Gorman, CFO Ruth Porat, Director Hutham S. Olayan, Co-President Institutional Securities Paul J. Taubman, and Director James W. Owens bought shares of MS stock. COO James A. Rosenthal sold 8,000 shares in July.
Celgene Corp. (CELG): Director Ernest Mario Bought 105,000 Shares
Director of Celgene Corp., Ernest Mario, bought 105,000 shares during the past week at an average price of $55.51. Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $25.69 billion; its shares were traded at around $55.51 with a P/E ratio of 20 and P/S ratio of 7.
On July 28, Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69. Celgene posted non-GAAP net income of $811 million, or non-GAAP diluted earnings per share of $1.72, for the first six months of 2011 as compared to non-GAAP net income of $618 million or non-GAAP diluted earnings per share of $1.32 in 2010.
Celgene Corp. is in the portfolios of John Hussman, Kenneth Fisher, and Mario Gabelli.
This month, CFO Jacqualyn A. Fouse, Director Ernest Mario, and Director Rodman L. Drake bought shares of CELG stock. Director Gilla Kaplan sold 20,000 shares in June.
Chesapeake Energy Corp. (CHK): Director V. Burns Hargis Bought 1,500 Shares
Director of Chesapeake Energy Corp., V. Burns Hargis, bought 1,500 shares on 08/04/2011 at an average price of $31.35. Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake Energy Corp. has a market cap of $20.62 billion; its shares were traded at around $31.35 with a P/E ratio of 10.7 and P/S ratio of 2.2. The dividend yield of Chesapeake Energy Corp. stocks is 1.1%. Chesapeake Energy Corp. had an annual average earnings growth of 9.8% over the past 10 years.
Chesapeake Energy Corp. is in the portfolios of Richard Snow, T Boone Pickens, Ruane Cunniff, Ronald Muhlenkamp, David Dreman, Charles Brandes, Arnold Schneider, Carl Icahn, and Mario Gabelli.
On July 28, Chesapeake Energy Corporation announced its 2011 second quarter financial and operational results. For the quarter, Chesapeake reported net income to common stockholders of $467 million ($0.68 per fully diluted common share), operating cash flow of $1.207 billion (defined as cash flow from operating activities before changes in assets and liabilities) and EBITDA of $1.289 billion.
In June, Chairman & CEO Aubrey K. Mcclendon and Executive Vice President & CFO Domenic J. Dell'osso Jr. bought shares of CHK stock. Director V. Burns Hargis bought 1,500 shares this month. Senior Vice President Human & Corporate Resources Martha A. Burger sold 40,000 shares this month.
For the complete list of stocks that bought by their company executives, go to: Insider Buys.
